期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

滤泡性淋巴瘤的临床特点、预后及治疗 被引量：4

Clinical manifestation, prognosis and treatment of follicular lymphoma
原文传递
导出
摘要 滤泡性淋巴瘤的发生率居非霍奇金淋巴瘤发病率的第二位，临床上疾病发展呈惰性，主要表现为无痛性淋巴结肿大。预后因素包括滤泡淋巴瘤国际预后指数（FLIPI）、肿瘤组织免疫微环境。免疫化疗已成为滤泡淋巴瘤的一线治疗方法，滤泡淋巴瘤一经诊断即应开始治疗，观察等待策略仅限于少数选择病例。造血干细胞移植适用于复发、难治的病例。 Follicular lymphoma accounts for 22.1% of non-Hodgkin lymphoma. It is an indolent lymphoma. The clinical feature is lymphadenopathy with/without marrow involvement. The prognostic factors include follicular lymphoma international prognosis index （FLIPI） and tumor infiltrating immune cells. The first-line therapy is immunochemotherapy with rituximab. In patients with refractory/relapes disease, stem cell transplantation is the choice.
作者 常乃柏(综述)
机构地区 卫生部北京医院血液科
出处 《白血病．淋巴瘤》 CAS 2009年第8期496-499,共4页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 滤泡型 预后 治疗 Lymphoma, follicular Prognosis Therapy
分类号 R733.4 [医药卫生—肿瘤] R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献31

  • 1Sato Y, Ichimura T, Takata K, et al. Duodenal follicular lymphomas share common charateristics with mucosa-associated lymphoid tissue lymphomas. J Clin Pathol, 2008, 61: 377-381.
  • 2Kim BK, Surti U, Pandya A, et al. Clinicophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphoma. Am J Surg Pathol, 2005, 29: 69-82.
  • 3Cong P, Raffeld M, Teruya-Feldstein J, et al. In situ localization follicular lymphoma: description and analysis by laser capture microdissection. Blood, 2002, 99: 3376-3382.
  • 4Roulland S, Navarro J, Grenot P, et al. Follicular lymphoma-like B cells in healthy individuals:a novel intermediate step in early lymphomagenesis. J Exp Med, 2006, 203: 2425-2431.
  • 5Solal-Celigni P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood, 2004, 104:1258-1265.
  • 6Farinha P, Masoudi H, Skinnider BP, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 2005, 106: 2169-2174.
  • 7Dave SS, Wright G, Tan B, et al. Predictor of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Eng J Med, 2004, 351: 2159-2169.
  • 8Byers R, Sakhinia E, Joseph P, et al. Clinical quantitation of immune signiture in follicular lymphoma by RT-PCR-based gene expression profiling. Blood, 2008, 111: 4764-4770.
  • 9Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infihrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 2006, 108: 2957-2960.
  • 10Taskinen M, Karjalainen-Lindsburg M, Leppa S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood,' 2008, 111: 4664-4667.

同被引文献40

  • 1Finn WG. Kroft SH New classifications for non-Hodgkin's lymphoma[J]. Cancer Treat Res, 1999,99: 1-26.
  • 2Sehulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systemic review and meta-analysis[J]. J Natl Cancer Inst,2007,99:706-714.
  • 3Canioni D, Salles G, Mounier N, et al. High numbers of tumor associated macrophages have an adverse prognostic value that can be circumvented by rituximad in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trail[J]. J Clin Oncol, 2008,26: 440-446.
  • 4Hirt C, Schuler F, Kiefer T, et al. Rapid and sustained dearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t (14;18)PCR monitoring in advanced stage follicular lymphoma patients[J].Br J Haematol, 2008,141: 631-640.
  • 5Van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without ritoximab during induction: results of a propective randomized phase Ⅲ intergroup trial[J]. Blood, 2006, 108 : 3295 3301.
  • 6Mclanghlin P, Hagemeister F B,Grillo-Lopez A J, et al. Rit uximab in indolent lymphoma: the single-agent pivotal trial [J]. Semin Oncol,1999,26(5 Suppl 14):79-87.
  • 7Ghielmini M, Rufibach K, Salles G, et al. Single agent ritux imab in patients with follicular or mantle cell lymphoma:clin ical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system:a study of the Swiss Group for Clinical Canc- er Research(SAKK) [J]. Ann Oncol, 2005, 16 (10): 1675- 1682.
  • 8Fisher RI, LeBlanc M, Press OW, et ah New treatment options have :',hanged the survival of patients with follicular lymphoma. J Clin Dncol, 2005, 23: 8447-8452.
  • 9Kahl B. Is there a role for "watch andwait" in follicular lymphoma in the rituximab era? Hematology Am Soc Hematol Educ Program. 2012, 2012: 433-438.
  • 10Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol, 2007, 25: 579-586.

引证文献4

二级引证文献15

白血病．淋巴瘤
2009年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部